Probiodrug AG Raises Additional EUR 15M

Your Source for Venture Capital and Private Equity Financings

Probiodrug AG Raises Additional EUR 15M

Back to Home

2012-01-04

HALLE/SAALE, GERMANY, Additional financing for the ongoing development of its glutaminyl cyclase inhibitor program. The lead compound is in clinical development for the treatment of Alzheimer's disease.

>> Click here for more funding data on Probiodrug AG

>> To export Probiodrug AG funding data to PDF and Excel, click here

(c) by Massinvestor, Inc. For contact info, please check out our about page.

>> Click here for in-depth research on 9,000+ startups and 5,000+ VC investors